PD0166285 is identified to inhibit Wee1 activity at nanomolar concentrations. The inhibitor abrogates G2/M checkpoint inducing early cell division. This G2 checkpoint abrogation by PD0166285 was demonstrated to kill cancer cells, there at a toxic highest dose of 0.5 muM in some cell lines for exposure periods of no longer than 6 hours. PD0166285 does not inhibit Cdc2/cyclin B but inhibits Chk1 kinase at a much higher concentration (3433 nM).
In vivo, PD0166285 at 0.5 μM concentration can inhibit Cdc2Y15/T14 phosphorylation in all cell lines tested, regardless of their p53 status and pharmacological targeting of WEE1 by PD0166285 sensitizes U251-FM GBM tumors to IR in vivo.
|Cell lines||B16 mouse melanoma cells|
|Preparation method||B16 cells (1 × 105 cells in 100 mm-dishes) are maintained in medium overnight. In addition, the cells are treated with (0, 0.5, 1.0, or 2.0 μM) PD0166285 (including DMSO vehicle) for indicated times. The cells are washed twice with phosphate-buffered saline (PBS). Next, the cells are trypsinized, so the cell numbers in each dish are determined by using a computed cell-counter (Sysmex CDA-500) according to manufacturer's recommendation.|
|Concentrations||0.5, 1, 2 μM|
|Incubation time||4 h, 24 h|
|Animal models||Nude mice with implanted GBM cells|
|Dosages||0, 20, 100, 200, or 400 µM in 100 µl|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO: ≥ 60 mg/mL|
In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma.
Mir SE, et al. Cancer Cell. 2010 Sep 14;18(3):244-57. PMID: 20832752.
Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line.
Hashimoto O, et al. BMC Cancer. 2006 Dec 19;6:292. PMID: 17177986.
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
Wang Y, et al. Cancer Res. 2001 Nov 15;61(22):8211-7. PMID: 11719452.
|Related Checkpoint Products|
Prexasertib dihydrochloride (LY2606368 HCl) is a potent and selective ATP competitive inhibitor of the Chk1 protein kinase with IC50s of <1 nM and 8 nM for CHK1 and CHK2, respectively.
Ipilimumab is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD.
BML-277 is a high efficient Chk2 inhibitors, IC50 is 15 nM.
AZD7762 hydrochloride is a potent ATP-competitive checkpoint kinase inhibitor with an IC50 of 5 and <10 nM for CHK1 and CHK2 respectively.
CHIR-124 is a novel and potent Chk1 inhibitor with IC50 of 0.3 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.